近日，来自阿姆斯特丹自由大学的Connie R. Jimenez团队在Science Translational Medicine杂志上发表了一篇题为 Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 的文章，他们对30个具有基因组和药理学特征的mCRC...
Colorectal cancerEpidermal growth factor receptorPrimary resistanceSecondary resistanceTargeted therapyThe development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major step forward in the treatment of ...
19. Van Cutsem, E., et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status...
[3] 2022 CSCO 非小细胞肺癌诊疗指南 [4] Peng Y,Li Q, Zhang J,et al. Update review of skin adverse events during treatment of lungcancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. BiosciTrends. 2019;12(6)...
☆Cancer Cell (IF=23.916):Genomic and Transcriptomic Determinants of Therapy Resistance and ImmuneLandscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. (2019 Jul 08) 尽管存在生物标志物分层,但抗EGFR抗体西妥昔单抗仅对一组结直肠癌有效。作者对35个RAS野生型CRCs中西妥昔单抗耐药情况的基因组...
Journal of Cancer Therapy 03 , 902-911 /Ka-On Lam, Victor Ho-Fun Lee. (2012) Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. Journal of Cancer Therapy 03 , 902-911 /Ka-OnLam, Victor Ho-FunLee. (2012) Metastatic Colorectal Cancer: Optimizing Treatment ...
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution This knowledge is being translated in the rational design of additional lines of therapy.Significance: Anti–EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heteroge...
【6】Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040–2048 (2007).*李强主持召开科技创新型企业座谈会：强化高质量科技供给 上海市委书记李强主持召开科技创新型企业座谈会，艾力斯董事长杜锦豪受邀出席并发言 **研发客 - 中国原研肺癌治疗药物（伏美...
BACKGROUND: Advances in the understanding of tumor biology have led to the development of targeted therapies allowing progress in colorectal cancer treatment. One of the most promising targets is the epidermal growth factor receptor (EGFR). METHOD: The presence and distribution of high- and low-aff...
4. Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase III PARADIGM trial. J Clin Oncol. 2022;40:17s ...